TRAVERE THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$17.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$5.40M, a 275.28% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$11.81M.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $6.25M, a 518.51% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$1.11M.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$85.00K.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$17.56M, a 170.92% decline from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $24.76M, a 1105.01% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.06M, a 16.70% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 25 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 28 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 31 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 31 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 34 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$17.21M 10-Q · filed 2026-08-04 | -$10.96M derived: sum of 3 quarters · filed 2026-08-04 | -$12.07M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||
| 2026-03-31 | -$11.81M 10-Q · filed 2026-05-04 | -$5.56M derived: sum of 2 quarters · filed 2026-05-04 | -$6.67M derived: sum of 3 quarters · filed 2026-05-04 | -$3.59M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||
| 2025-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $5.14M derived: sum of 2 quarters · filed 2026-02-19 | $8.22M derived: sum of 3 quarters · filed 2026-08-04 | -$85.00K 10-K · filed 2026-02-19 | |||||||||
| 2025-09-30 | -$1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.97M derived: sum of 2 quarters · filed 2026-08-04 | -$6.33M 10-Q · filed 2025-10-30 | -$5.32M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||
| 2025-06-30 | $3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$5.22M 10-Q · filed 2026-08-04 | -$4.21M derived: sum of 3 quarters · filed 2026-08-04 | -$7.14M derived: sum of 4 quarters · filed 2026-08-04 | |||||||||
| 2025-03-31 | -$8.30M 10-Q · filed 2026-05-04 | -$7.29M derived: sum of 2 quarters · filed 2026-05-04 | -$10.23M derived: sum of 3 quarters · filed 2026-05-04 | -$1.03M derived: sum of 4 quarters · filed 2026-05-04 | |||||||||
| 2024-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$1.92M derived: sum of 2 quarters · filed 2026-02-19 | $7.28M derived: sum of 3 quarters · filed 2026-02-19 | -$17.56M 10-K · filed 2026-02-19 | |||||||||
| 2024-09-30 | -$2.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $6.27M derived: sum of 2 quarters · filed 2025-10-30 | -$18.57M 10-Q · filed 2025-10-30 | -$1.28M derived: sum of 4 quarters · filed 2026-02-19 | |||||||||
| 2024-06-30 | $9.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$15.64M 10-Q · filed 2025-08-06 | $1.65M derived: sum of 3 quarters · filed 2026-02-19 | $5.81M derived: sum of 4 quarters · filed 2026-02-19 | |||||||||
| 2024-03-31 | -$24.84M 10-Q · filed 2025-05-01 | -$7.55M derived: sum of 2 quarters · filed 2026-02-19 | -$3.39M derived: sum of 3 quarters · filed 2026-02-19 | $273.00K derived: sum of 4 quarters · filed 2026-02-19 | |||||||||
| 2023-12-31 | $17.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $21.45M derived: sum of 2 quarters · filed 2026-02-19 | $25.11M derived: sum of 3 quarters · filed 2026-02-19 | $24.76M 10-K · filed 2026-02-19 | |||||||||
| 2023-09-30 | $4.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $7.82M derived: sum of 2 quarters · filed 2024-10-31 | $7.47M 10-Q · filed 2024-10-31 | $9.72M derived: sum of 4 quarters · filed 2025-02-21 | |||||||||
| 2023-06-30 | $3.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.31M 10-Q · filed 2024-08-01 | $2.51M 10-Q · filed 2023-08-03 | $5.56M derived: sum of 3 quarters · filed 2025-02-21 | $8.28M derived: sum of 4 quarters · filed 2025-02-21 | ||||||||
| 2023-03-31 | -$351.00K 10-Q · filed 2024-05-06 | -$627.00K 10-Q · filed 2023-05-04 | $1.90M derived: sum of 2 quarters · filed 2025-02-21 | $4.62M derived: sum of 3 quarters · filed 2025-02-21 | $6.31M derived: sum of 4 quarters · filed 2025-02-21 | ||||||||
| 2022-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $4.97M derived: sum of 2 quarters · filed 2025-02-21 | $6.66M derived: sum of 3 quarters · filed 2025-02-21 | $2.06M 10-K · filed 2025-02-21 | |||||||||
| 2022-09-30 | $2.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $4.41M derived: sum of 2 quarters · filed 2023-11-07 | -$198.00K 10-Q · filed 2023-11-07 | -$364.00K 10-Q · filed 2022-10-27 | $6.59M derived: sum of 4 quarters · filed 2024-02-20 | ||||||||
| 2022-06-30 | $1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.92M 10-Q · filed 2023-08-03 | $3.88M derived: sum of 3 quarters · filed 2024-02-20 | $182.00K derived: sum of 4 quarters · filed 2024-02-20 | |||||||||
| 2022-03-31 | -$4.61M 10-Q · filed 2023-05-04 | $2.19M derived: sum of 2 quarters · filed 2024-02-20 | -$1.51M derived: sum of 3 quarters · filed 2024-02-20 | -$7.18M derived: sum of 4 quarters · filed 2024-02-20 | |||||||||
| 2021-12-31 | $6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $3.10M derived: sum of 2 quarters · filed 2024-02-20 | -$2.58M derived: sum of 3 quarters · filed 2024-02-20 | $2.47M 10-K · filed 2024-02-20 | |||||||||
| 2021-09-30 | -$3.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$9.37M derived: sum of 2 quarters · filed 2022-10-27 | -$4.33M 10-Q · filed 2022-10-27 | $1.91M 10-Q · filed 2021-10-29 | |||||||||
| 2021-06-30 | -$5.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$632.00K 10-Q · filed 2022-08-04 | $4.68M 10-Q · filed 2021-07-29 | ||||||||||
| 2021-03-31 | $5.04M 10-Q · filed 2022-05-05 | -$4.44M 10-Q · filed 2021-05-06 | |||||||||||
| 2020-09-30 | $6.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $6.36M derived: sum of 2 quarters · filed 2021-10-29 | -$10.21M 10-Q · filed 2021-10-29 | ||||||||||
| 2020-06-30 | $170.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$16.41M 10-Q · filed 2021-07-29 | |||||||||||
| 2020-03-31 | -$16.58M 10-Q · filed 2021-05-06 | ||||||||||||
| 2019-09-30 | -$1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $8.06M derived: sum of 2 quarters · filed 2020-11-05 | $4.96M 10-Q · filed 2020-11-05 | ||||||||||
| 2019-06-30 | $9.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $6.30M 10-Q · filed 2020-07-31 | |||||||||||
| 2019-03-31 | -$3.10M 10-Q · filed 2020-05-11 | ||||||||||||
| 2018-09-30 | $9.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $16.32M derived: sum of 2 quarters · filed 2019-10-30 | $6.99M 10-Q · filed 2019-10-30 | $6.80M 10-Q · filed 2018-11-01 | $9.22M derived: sum of 4 quarters · filed 2019-10-30 | ||||||||
| 2018-06-30 | $6.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$2.81M 10-Q · filed 2019-08-06 | -$580.00K derived: sum of 3 quarters · filed 2019-08-06 | $3.30M derived: sum of 4 quarters · filed 2019-08-06 | |||||||||
| 2018-03-31 | -$9.33M 10-Q · filed 2019-05-07 | -$7.10M derived: sum of 2 quarters · filed 2019-05-07 | -$3.22M derived: sum of 3 quarters · filed 2019-05-07 | -$2.05M derived: sum of 4 quarters · filed 2019-05-07 | |||||||||
| 2017-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | $6.11M derived: sum of 2 quarters · filed 2018-11-01 | $7.28M derived: sum of 3 quarters · filed 2018-11-01 | $2.66M 10-K · filed 2018-07-06 | |||||||||
| 2017-09-30 | $3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $5.05M derived: sum of 2 quarters · filed 2018-11-01 | $425.00K 10-Q · filed 2018-11-01 | $6.82M derived: sum of 4 quarters · filed 2018-11-01 | |||||||||
| 2017-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | -$3.46M 10-Q · filed 2018-08-03 | $2.94M derived: sum of 3 quarters · filed 2018-08-03 | $5.56M derived: sum of 4 quarters · filed 2018-08-03 | |||||||||
| 2017-03-31 | -$4.63M 10-Q · filed 2018-07-06 | -$4.79M 10-Q · filed 2017-05-05 | $1.77M derived: sum of 2 quarters · filed 2018-07-06 | $4.40M derived: sum of 3 quarters · filed 2018-07-06 | $8.61M derived: sum of 4 quarters · filed 2018-07-06 | ||||||||
| 2016-12-31 | $6.39M derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | $9.02M derived: sum of 2 quarters · filed 2018-07-06 | $13.23M derived: sum of 3 quarters · filed 2018-07-06 | $9.67M 10-K · filed 2018-07-06 | |||||||||
| 2016-09-30 | $2.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $6.84M derived: sum of 2 quarters · filed 2017-11-07 | $3.28M 10-Q · filed 2017-11-07 | $7.83M derived: sum of 4 quarters · filed 2018-07-06 | |||||||||
| 2016-06-30 | $4.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $650.00K 10-Q · filed 2017-08-09 | $5.20M derived: sum of 3 quarters · filed 2018-07-06 | $7.45M derived: sum of 4 quarters · filed 2018-07-06 | |||||||||
| 2016-03-31 | -$3.56M 10-Q · filed 2017-05-05 | $991.00K derived: sum of 2 quarters · filed 2018-07-06 | $3.24M derived: sum of 3 quarters · filed 2018-07-06 | $1.93M derived: sum of 4 quarters · filed 2018-07-06 | |||||||||
| 2015-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | $6.80M derived: sum of 2 quarters · filed 2018-07-06 | $5.49M derived: sum of 3 quarters · filed 2018-07-06 | $3.38M 10-K · filed 2018-07-06 | |||||||||
| 2015-09-30 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $934.00K derived: sum of 2 quarters · filed 2016-11-04 | -$1.17M 10-Q · filed 2016-11-04 | -$852.00K 10-Q · filed 2015-11-06 | $5.67M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||
| 2015-06-30 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$3.42M 10-Q · filed 2016-08-05 | -$4.37M 10-Q · filed 2015-08-10 | $3.42M derived: sum of 3 quarters · filed 2017-03-01 | $10.64M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||
| 2015-03-31 | -$2.11M 10-Q · filed 2016-05-05 | -$3.15M 10-Q · filed 2015-05-11 | $4.73M derived: sum of 2 quarters · filed 2017-03-01 | $11.95M derived: sum of 3 quarters · filed 2017-03-01 | $16.92M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||
| 2014-12-31 | $6.84M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $14.06M derived: sum of 2 quarters · filed 2017-03-01 | $19.03M derived: sum of 3 quarters · filed 2017-03-01 | $20.60M 10-K · filed 2017-03-01 | $20.30M 10-K · filed 2015-03-11 | ||||||||
| 2014-09-30 | $7.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $12.19M derived: sum of 2 quarters · filed 2015-11-06 | $13.76M 10-Q · filed 2015-11-06 | $13.76M 10-Q · filed 2014-11-13 | $14.76M derived: sum of 4 quarters · filed 2016-02-26 | ||||||||
| 2014-06-30 | $4.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $6.55M 10-Q · filed 2015-08-10 | $6.55M 10-Q · filed 2014-08-14 | $7.55M derived: sum of 3 quarters · filed 2016-02-26 | $9.08M derived: sum of 4 quarters · filed 2016-02-26 | ||||||||
| 2014-03-31 | $1.58M 10-Q · filed 2015-05-11 | $1.64M 10-Q · filed 2014-05-15 | $2.58M derived: sum of 2 quarters · filed 2016-02-26 | $4.11M derived: sum of 3 quarters · filed 2016-02-26 | $7.17M derived: sum of 4 quarters · filed 2016-02-26 | ||||||||
| 2013-12-31 | $1.00M derived: 10-K 12 month − 10-Q/A 9 month · filed 2016-02-26 | $2.53M derived: sum of 2 quarters · filed 2016-02-26 | $5.59M derived: sum of 3 quarters · filed 2016-02-26 | $2.84M 10-K · filed 2016-02-26 | $2.84M 10-K · filed 2014-03-28 | $6.33M 10-K/A · filed 2015-07-09 | |||||||
| 2013-09-30 | $1.53M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2015-07-09 | $4.59M derived: sum of 2 quarters · filed 2015-07-09 | $1.84M 10-Q/A · filed 2015-07-09 | -$313.36K 10-Q · filed 2013-11-13 | $4.15M derived: sum of 4 quarters · filed 2015-07-09 | $5.33M 10-Q/A · filed 2015-07-09 | $3.18M 10-Q · filed 2013-11-13 | ||||||
| 2013-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $312.00K 10-Q · filed 2014-08-14 | $2.62M derived: sum of 3 quarters · filed 2015-07-09 | $3.20M derived: sum of 4 quarters · filed 2015-07-09 | $3.80M 10-Q · filed 2013-09-16 | ||||||||
| 2013-03-31 | -$2.75M 10-Q · filed 2014-05-15 | -$2.39M 10-Q · filed 2013-07-24 | -$447.25K derived: sum of 2 quarters · filed 2015-07-09 | $138.90K derived: sum of 3 quarters · filed 2015-07-09 | $1.10M 10-Q/A · filed 2013-09-16 | ||||||||
| 2012-12-31 | $2.30M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2015-07-09 | $2.89M derived: sum of 2 quarters · filed 2015-07-09 | $2.98M 10-K/A · filed 2015-07-09 | ||||||||||
| 2012-11-30 | $1.66K 10-Q · filed 2013-03-06 | ||||||||||||
| 2012-09-30 | $586.15K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2015-07-09 | $675.25K 10-Q/A · filed 2015-07-09 | |||||||||||
| 2012-08-31 | $500.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-10-10 | $1.00K 10-Q · filed 2012-10-10 | |||||||||||
| 2012-06-30 | $199.97K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2013-09-16 | $89.10K 10-Q · filed 2013-09-16 | |||||||||||
| 2012-05-31 | $500.00 10-Q · filed 2012-08-08 | ||||||||||||
| 2012-03-31 | -$110.86K 10-Q/A · filed 2013-09-16 | ||||||||||||
| 2011-11-30 | $500.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-03-06 | $1.00K derived: sum of 2 quarters · filed 2013-03-06 | $1.50K 10-Q · filed 2013-03-06 | ||||||||||
| 2011-08-31 | $500.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-10-10 | $1.00K 10-Q · filed 2012-10-10 | |||||||||||
| 2011-05-31 | $500.00 10-Q · filed 2012-08-08 | ||||||||||||
| 2010-11-30 | $500.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-01-11 | $1.50K 10-Q · filed 2012-01-11 | |||||||||||
| 2010-08-31 | $1.00K 10-Q/A · filed 2012-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |